CPT 80305: Presumptive Drug Test, Visual Read
Commercial payers pay $40 on average nationally for this procedure.
CPT code 80305 describes a presumptive drug test performed by a laboratory analyst using direct visual/optical observation only (no instrument assistance) to screen for one or more drug classes on a single date; the service type is point-of-care/clinical laboratory screening, and the typical site of service is clinical laboratory or point-of-care testing location where visually read assays (e.g., immunoassay dipstick or cassette) are completed.
Customize your policy alerts
Sign up for cpt 80305 policy alerts
Get alerted when payer policies referencing 80305 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
For CPT 80305, BUCA’s average commercial rate sits at $39.7, serving as a useful midpoint for national commercial pricing. Blue Cross Blue Shield has the highest variability with a P75–P25 spread of $34.5 ($72.8 − $37.3), driven by a wide top-end maximum of $295.4 that pulls the mean above most peers. Aetna and Cigna exhibit similar central tendencies near the low teens, while UnitedHealth Group’s median of $7.6 is notably lower than its peers’ medians.
Assessing dispersion shows UnitedHealth Group and Aetna have the tightest interquartile ranges: UnitedHealth Group’s P75–P25 is $7.0 ($12.6 − $5.6) and Aetna’s is $6.0 ($15.0 − $9.0), indicating more compressed commercial pricing. Blue Cross Blue Shield is the widest at $34.5, with Cigna and BUCA in between (Cigna IQR $8.4; BUCA IQR $21.2), highlighting material differences in commercial rate concentration across payers.